Skip to main content

Research Repository

Advanced Search

Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease

People Involved

Simon Fraser

Dr Michael Crooks

Dr Michael Crooks m.g.crooks@hull.ac.uk
Senior Clinical Lecturer in Respiratory Medicine

Project Description

An in silico computational model of sarcoidosis

Type of Project Project
Status Project Complete
Funder(s) Foundation for Sarcoidosis Research
Value £117,415.00
Project Dates Jun 30, 2017 - Aug 31, 2020

You might also like

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Aug 31, 2022
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.Read More about Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.

IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial May 5, 2017 - Aug 31, 2022
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per ye... Read More about IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial.

AX-8 Clinical Research Collaboration Jun 1, 2016 - May 31, 2018
Primary:
Study the efficacy of compound AX-8 in suppressing cough and upper airway symptoms in subjects with cough hypersensitivity syndrome.

Secondary:
Study the safety of compound AX-8.